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RESPONSE TO COMMENT ON LEESE ET AL.
Progression of Diabetes Retinal Status
Within Community Screening Programs
and Potential Implications for Screening
Intervals. Diabetes Care 2015;38:488–494
Diabetes Care 2015;38:e209–e210 | DOI: 10.2337/dci15-0015
We thank Ziemssen et al. (1) for their com-
ments on our recent article (2). The under-
lying issue is how much evidence is
required before screening intervals are
changed. Screening is a population-based
activity, designed for maximum beneﬁt of
the population and the safety of the indi-
vidual. Using a variable screening interval
depending on risk could enable resources
to be directed toward patients at the high-
est risk of visual loss.
We agree with Ziemssen et al. that
some patients with clinically signiﬁcant
maculopathy will require treatment on
referral to the ophthalmology clinic and
apologize if we gave the wrong impres-
sion. We were trying to indicate that the
vast majority of patients with prolifera-
tive retinopathy will require early laser
treatment, while the majority of patients
referred from screening with macular
changes do not require any treatment
as most do not have macular edema
(just exudates or hemorrhage), and of
those who do,many do not have clinically
signiﬁcant macular edema. Clearly, ad-
vances in the treatment of age-related
macular degeneration and possibly dia-
betic macular edema are progressing
quickly but that does not invalidate the
conclusions of our study. The issues high-
light the differences between “referable”
and “treatable” eye diseases, which are
well recognized within screening, and
the deﬁnitions of which are actually very
similar in England and Scotland when
looking at the grading schemes.
The reviews quoted by Ziemssen et al.
actually indicated that increasing the
screening interval may be safe for low-
risk patients (3,4), although Taylor-Phillips
et al. (4) did not specify which of the stud-
ies they reviewed were genuinely low risk,
but just accepted the authors’ deﬁnitions.
In addition, nonattenders at screening are
at high risk of visual loss and thus would
not be eligible for longer screening inter-
vals. Also, Taylor-Phillips et al. identiﬁed
three studies supporting ongoing annual
screening, where one was a simulation
study, one was from 1991 with different
technology costs and patient proﬁles, and
one was from Taiwanwith different health
care provisions. We have tried to be clear
on what we deﬁne as low risk. Namely, 1)
two successive baseline screening epi-
sodes with no evidence of any retinopa-
thy, which would thus exclude any
patient who did not attend and minimize
the risk of missing retinopathy due to
grading errors, and 2) screenings con-
ducted by a robust internal and external
quality-assured screening program. This
addresses the heterogeneity of screening
delivery and allows for further develop-
ments in the future. We also stated that
low risk could be further reﬁned if there
was additional supportive evidence by
using duration of diabetes, blood pres-
sure, HbA1c, and diabetes type.
It is hard to decide whether screening
intervals should increase for patients in
whom the risk of sight-threatening reti-
nopathy is very low, but the decision is
linked to using limited resources to im-
proveaccessibility to screening, education,
new developments, and management of
high-risk patients. Unfortunately, any use-
ful randomized controlled trial to detect
impaired vision is unlikely to be practical
because of the large number of patients
required, as described in our article. We
welcome a debate as to what evidence
would be required to persuade patients,
patient advocates, public health physi-
cians, diabetologists, ophthalmologists,
health service managers, and others.
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